CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
Famotidine 20 MG +1 moredrug
Likely dose
Famotidine 20 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03554291
NCT03554291Phase 2Completed
CompareCT.gov

Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension

University of Washington·interventional·Posted Jun 13, 2018·Updated Aug 9, 2024

In Brief

A Phase 2 clinical trial evaluating Famotidine 20 MG and Placebo for Pulmonary Arterial Hypertension and Right Heart Failure. Completed, enrolled 80 participants across 1 site.

Detailed Summary

This is a Phase 2, single-center, randomized placebo controlled trial of famotidine (an H2 receptor antagonist) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of famotidine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension, Right Heart Failure
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 13, 2018
Enrollment StartMay 1, 2019
Primary CompletionJul 11, 2023
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 8.1 years ago

Interventions

Famotidine 20 MGdrug

Famotidine 20 mg capsule taken daily for 24 weeks.

Placeboother

Placebo capsule taken daily for 24 weeks.